Biotech bil­lion­aire spends $88M to re­or­ga­nize his long-suf­fer­ing bio­engi­neer­ing busi­ness­es, hands off CEO role

Biotech bil­lion­aire Ran­dal Kirk is look­ing for a fresh start with the new year.

He has whipped up the lat­est — and most com­pre­hen­sive — in a se­ries of re­or­ga­ni­za­tions for his mul­ti­ple bio­engi­neer­ing ven­tures at In­trex­on, tak­ing a long-de­layed step to the ex­ec­u­tive chair­man’s role, re­nam­ing the com­pa­ny and pro­mot­ing a top ex­ec to the CEO’s role.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER